Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757808 · ClinicalTrials.gov registry record · Phase 1
A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
A Phase 1 study of Pulmonary Arterial Hypertension, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01757808: Completed Phase 1 study of Pulmonary Arterial Hypertension, sponsored by University of Chicago.
NCT01757808 is a Phase 1 study of Pulmonary Arterial Hypertension that has completed, run by University of Chicago. The registered enrollment target is 12 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01757808, a Phase 1 study of Pulmonary Arterial Hypertension, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety of ranolazine in people with pulmonary arterial hypertension (PAH) and who are receiving 1 or more background PAH therapies: ambrisentan, sildenafil,tadalafil, epoprostenol, treprostinil (IV, SC, inhaled), or iloprost. The primary objective is: * To estimate the effect of ranolazine administration on acute hemodynamics. * To assess safety of ranolazine acutely over 6 hrs in the catheterization lab and after 12 weeks of therapy * To assess changes in right ventricular function after 12 weeks of therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ranolazine
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01757808 record still lists
NCT01757808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01757808 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01757808 about?
NCT01757808 is a clinical study titled "A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension". The purpose of this study is to assess the safety of ranolazine in people with pulmonary arterial hypertension (PAH) and who are receiving 1 or more background PAH therapies: ambrisentan, sildenafil,tadalafil, epoprostenol, treprostinil (IV, SC, inhaled), or iloprost. The primary objective is: * To...
What is the current status of trial NCT01757808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-08. Estimated completion is 2015-01.
What conditions does trial NCT01757808 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT01757808?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01757808?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01757808 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01757808's enrollment target sits among peer trials
12 57th of 63 higher than 6 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 1
-
Subcutaneous Elafin in Healthy Subjects
COMPLETED · Phase 1
-
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 1
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia